相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety
Matti Aapro et al.
ONCOLOGIST (2015)
Glioblastoma multiforme: Pathogenesis and treatment
Constantinos Alifieris et al.
PHARMACOLOGY & THERAPEUTICS (2015)
HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress
Runping Liu et al.
PLOS ONE (2015)
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies
Akinori Sato
ONCOTARGETS AND THERAPY (2015)
The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors
Sandra Liekens et al.
ONCOTARGET (2015)
Nuclear translocation of fibroblast growth factor-2 (FGF2) is regulated by Karyopherin-β2 and Ran GTPase in human glioblastoma cells
Feng Wang et al.
ONCOTARGET (2015)
Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir et al.
CLINICAL CANCER RESEARCH (2015)
Quantification of Central Substance P Receptor Occupancy by Aprepitant Using Small Animal Positron Emission Tomography
Tadashi Endo et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2015)
The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture
Elizabeth M. Haley et al.
CANCER LETTERS (2014)
Preclinical evidence that SSR128129E-A novel small-molecule multi-fibroblast growth factor receptor blocker - Radiosensitises human glioblastoma
Isabelle Ader et al.
EUROPEAN JOURNAL OF CANCER (2014)
Blocking the bFGF/STAT3 interaction through specific signaling pathways induces apoptosis in glioblastoma cells
Jingchao Wu et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations
Marianne Kraus et al.
LEUKEMIA RESEARCH (2014)
Treatment with the NK1 Antagonist Emend Reduces Blood Brain Barrier Dysfunction and Edema Formation in an Experimental Model of Brain Tumors
Elizabeth Harford-Wright et al.
PLOS ONE (2014)
CUSP9*treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
Richard E. Kast et al.
ONCOTARGET (2014)
Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways
Ramesh B. Batchu et al.
PHARMACEUTICALS (2014)
Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells
F. Rappa et al.
BIOCHIMIE (2013)
Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage
Tim De Schutter et al.
BMC MEDICAL GENOMICS (2013)
Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types
Matti S. Aapro et al.
CANCER TREATMENT REVIEWS (2013)
Cidofovir: A Novel Antitumor Agent for Glioblastoma
Piotr Hadaczek et al.
CLINICAL CANCER RESEARCH (2013)
Safety of neurokinin-1 receptor antagonists
Miguel Munoz et al.
EXPERT OPINION ON DRUG SAFETY (2013)
Involvement of substance P and the NK-1 receptor in cancer progression
Miguel Munoz et al.
PEPTIDES (2013)
A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Richard E. Kast et al.
ONCOTARGET (2013)
Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals
Mark M. Manak et al.
AIDS (2010)
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
Miguel Munoz et al.
INVESTIGATIONAL NEW DRUGS (2010)
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug
R. E. Kast
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question
Richard E. Kast
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Topical treatment of CIN 2+by cidofovir: Results of a phase II, double-blind, prospective, placebo-controlled study
C. Van Pachterbeke et al.
GYNECOLOGIC ONCOLOGY (2009)
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas
Toshimasa Akazawa et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Anti-HIV drugs for cancer therapeutics: back to the future?
Warren A. Chow et al.
LANCET ONCOLOGY (2009)
Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection
Sharon S. Lieberman-Blum et al.
CLINICAL THERAPEUTICS (2008)
Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo
JoellJ. Gills et al.
CLINICAL CANCER RESEARCH (2007)
The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines
M Muñoz et al.
NEUROPEPTIDES (2005)
The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig
C Anthonypillai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant
M Bergström et al.
BIOLOGICAL PSYCHIATRY (2004)
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections
E De Clercq
CLINICAL MICROBIOLOGY REVIEWS (2003)
分享论文
